Previous Close | 35.60 |
Open | 35.95 |
Bid | 34.80 x 0 |
Ask | 35.80 x 0 |
Day's Range | 34.85 - 35.95 |
52 Week Range | 32.00 - 50.80 |
Volume | |
Avg. Volume | 33,895 |
Market Cap | 427.259M |
Beta (5Y Monthly) | 0.56 |
PE Ratio (TTM) | 40.70 |
EPS (TTM) | 0.86 |
Earnings Date | Feb 13, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | Apr 11, 2013 |
1y Target Est | 68.67 |
Subscribe to Yahoo Finance Plus to view Fair Value for BSLN.SW
Allschwil, Switzerland, March 11, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the continued strong sales performance of the antifungal Cresemba® (isavuconazole) by its license partner Pfizer Inc. in the Asia Pacific region and China exceeded the sales threshold triggering a USD 1.25 million milestone payment. David Veitch, Basilea’s
Increased Cresemba® and Zevtera®-related revenue of CHF 150.3 million (+22.9% year-on-year) at upper end of guidanceOperating profit of CHF 19.2 million and net profit of CHF 10.5 million, significantly above guidanceAddition of three new anti-infective assets to clinical portfolio, including phase-3-ready antifungal fosmanogepixStrong cash and restricted cash position of CHF 64.3 million, after fully absorbing investments into portfolio expansion and accelerated debt reduction FY 2024 guidance:
Allschwil, Switzerland, January 19, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the sales of the antifungal Cresemba® (isavuconazole) in 2023 by its partner Knight Therapeutics Inc. (“Knight”, TSX: GUD) in Latin America exceeded the threshold triggering the first sales milestone payment for this region. David Veitch, Chief Executive